{"id":826710,"date":"2025-03-18T06:03:09","date_gmt":"2025-03-18T10:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/"},"modified":"2025-03-18T06:03:09","modified_gmt":"2025-03-18T10:03:09","slug":"from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/","title":{"rendered":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod<sup>\u00ae<\/sup> 5 in Adults and Children with Type 1 Diabetes<\/b><\/p>\n<p>ACTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.myomnipod.com%2F&amp;esheet=54224605&amp;newsitemid=20250316052311&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=d207930eb3761a20c861afe74ce580bd\">tubeless insulin pump<\/a> technology with its Omnipod<sup>\u00ae<\/sup> brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18<sup>th<\/sup> International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) taking place March 19 \u2013 22, 2025 in Amsterdam, the Netherlands, and online.\n<\/p>\n<p>\nThe study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with type 1 diabetes in France, the U.K., and Belgium using Omnipod 5, compared with those using multiple daily injections (MDI) with a continuous glucose monitor (CGM). RADIANT is the first randomized controlled trial to assess the direct transition from MDI to an automated insulin delivery (AID) system in adults and children who were not previously achieving clinical targets for HbA1c with MDI. It is also the first randomized clinical trial to assess the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre<sup>\u00ae<\/sup> 2 family sensor.\n<\/p>\n<p>\nThe RADIANT results will be discussed at an Insulet-sponsored symposium, \u201cTransform Your Clinical Care with Omnipod 5: Revolutionizing Diabetes Management,\u201d being held on Wednesday, March 19 from 2:40 p.m. \u2013 4:10 p.m. CET in Hall E.\n<\/p>\n<p>\nThe symposium will be presented by:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDr. Emma Wilmot, PhD, FRCP, Associate Professor, University of Nottingham, School of Medicine, Nottingham, U.K. \u2013 Omnipod 5 Delivers Transformative Glycemic Outcomes \u2013 Sharing the Latest Breaking Results\n<\/li>\n<li>\nDr. Chantal Mathieu, MD, PhD, Professor of Medicine, Katholieke Universiteit Leuven, Belgium \u2013 How Omnipod 5 is Providing an Unparalleled User Experience\n<\/li>\n<li>\nDr. Brynn Marks, MD, MSHPEd, Director of Technology and Attending Physician, Children\u2019s Hospital of Philadelphia, Assistant Professor, CE Perelman School of Medicine of the University of Pennsylvania, U.S. \u2013 Accelerating AID for All \u2013 Reaching the Broadest Populations Effectively\n<\/li>\n<li>\nDr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer, will provide a Company update on future innovations at the symposium\n<\/li>\n<\/ul>\n<p>\nAdditionally, Dr. Wilmot will be conducting an oral presentation about RADIANT on Saturday, March 22, from 10:50 a.m. \u2013 11:00 a.m. A total of 11 presentations and posters on the Omnipod 5 AID System and the Omnipod DASH<sup>\u00ae<\/sup> Insulin Management System will be presented at ATTD (all times CET)<b>:<\/b><\/p>\n<p><b>Oral Presentations<\/b><\/p>\n<p><i>Thursday, March 20<\/i><\/p>\n<p>\nOral Presentation SO031 (4:15 p.m. \u2013 4:20 p.m., Station 04, Session 09) \u2013<b> How Do Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Compare for Persons with Type 1 Versus Type 2 Diabetes? Learnings Across Studies<\/b> with Dr. Viral Shah\n<\/p>\n<p>\nOral Presentation SO034 (4:30 p.m. \u2013 4:35 p.m., Station 04, Session 09) \u2013 <b>Simplified Meal Bolus Strategies for the Omnipod 5 Automated Insulin Delivery (AID) System in People with Type 2 Diabetes (T2D): Sub-Analysis of the SECURE-T2D Study<\/b> with Dr. Georgia Davis\n<\/p>\n<p><i>Friday, March 21<\/i><\/p>\n<p>\nOral Presentation SO058 (4:50 p.m. \u2013 4:55 p.m., Station 02, Session 16) \u2013<b> Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System<\/b> with Dr. Carol Levy\n<\/p>\n<p>\nOral Presentation SO060 (5:00 p.m. \u2013 5:05 p.m., Station 02, Session 16) \u2013 <b>Real-World Glycemic Outcomes of &gt;19,100 Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management<\/b> with Dr. Eden Miller\n<\/p>\n<p><i>Saturday, March 22<\/i><\/p>\n<p>\nOral Presentation OP046 (10:50 a.m. \u2013 11:00 a.m., Hall D1, Session 06) \u2013<b> Efficacy of the Omnipod 5 Automated Insulin Delivery (AID) System Compared with Multiple Daily Injections in Type 1 Diabetes: A Multinational Randomized Controlled Trial (RADIANT) <\/b>with Dr. Emma Wilmot\n<\/p>\n<p>\nOral Presentation OP056 (11:30 a.m. \u2013 11:40 a.m., Hall D1, Session 08) \u2013 <b>Impact of Lowering Target Glucose Setting with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Use<\/b> with Dr. Gregory Forlenza\n<\/p>\n<p>\nOral Presentation OP087 (1:45 p.m. \u2013 1:55 p.m., Hall E, Session 13) \u2013<b> Improved Glycemic Outcomes with the Omnipod 5 System in People with Type 2 Diabetes Using GLP 1 <\/b>\u2013 <b>Receptor Agonists or SGLT2 Inhibitors: Sub-Analysis of the SECURE-T2D Study<\/b> with Davida Kruger, NP\n<\/p>\n<p><b><i>Poster Presentations<\/i><\/b><\/p>\n<p>\ne-Poster PV076 \u2013 <b>Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 1 Diabetes in the United Kingdom and Germany<\/b> with Dr. Jackie Elliott\n<\/p>\n<p>\ne-Poster PV062 \u2013 <b>Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Children and Adolescents with Type 1 Diabetes in the United Kingdom and Germany<\/b> with Dr. Torben Biester\n<\/p>\n<p>\ne-Poster PV328 \u2013 <b>Real-World Data of 13,827 French T1D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform<\/b> with Pr. Nathalie Jeandidier\n<\/p>\n<p>\ne-Poster PV329 \u2013<b> Real-World Data of 934 French T2D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform<\/b> with Pr. Nathalie Jeandidier\n<\/p>\n<p><b><i>Additional Exhibit Hall Activities and Programs<\/i><\/b><\/p>\n<p>\nIn the exhibition hall, delegates can look forward to a variety of interactive experiences at the Omnipod booth, showcasing how Omnipod 5 is transforming lives globally. Delivering the latest insights and learnings to audiences worldwide, attendees will have the unique opportunity to attend live recordings of the increasingly popular podcasts, <i>Within Range: Demystifying Diabetes Tech<\/i>, and the podcast specially curated for people living with diabetes, <i>TypeCast: Life Between the Lines<\/i>.\n<\/p>\n<p>\nThere will also be a Baird hosted webcast, \u201cTakeaways with Dr. Trang Ly\u201d, that recaps the highlights, new clinical data, and updates from ATTD. This will take place on Friday, March 21, 4:00 p.m. from Insulet\u2019s exhibition booth. A link to the webcast will be available on the Investor Relations section of the Company&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.insulet.com%2Foverview%2Fdefault.aspx&amp;esheet=54224605&amp;newsitemid=20250316052311&amp;lan=en-US&amp;anchor=investors.insulet.com&amp;index=2&amp;md5=6816294734f753e1031f33a27b10cbad\">investors.insulet.com<\/a>, under \u201cEvents and Presentations,\u201d and will be archived for future replay.\n<\/p>\n<p><b><i>About Insulet Corporation:<\/i><\/b><\/p>\n<p>\nInsulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet\u2019s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.insulet.com%2F&amp;esheet=54224605&amp;newsitemid=20250316052311&amp;lan=en-US&amp;anchor=insulet.com&amp;index=3&amp;md5=3053e9606d651790f43d5f8b0313e019\">insulet.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54224605&amp;newsitemid=20250316052311&amp;lan=en-US&amp;anchor=omnipod.com&amp;index=4&amp;md5=a03804a9aa05818314052d348bc0dbb2\">omnipod.com<\/a>.\n<\/p>\n<p>\n\u00a92025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other trademarks are the property of their respective owners.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250316052311\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250316052311\/en\/<\/a><\/span><\/p>\n<p><b><i>Investor Relations:<br \/>\n<\/i><\/b><br \/>June Lazaroff<br \/>\n<br \/>Senior Director, Investor Relations<br \/>\n<br \/>(978) 600-7717<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jlazaroff@insulet.com\">jlazaroff@insulet.com<\/a><\/p>\n<p><b><i>Media:<br \/>\n<\/i><\/b><br \/>Angela Geryak Wiczek<br \/>\n<br \/>Senior Director, Corporate Communications<br \/>\n<br \/>(978) 932-0611<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:awiczek@insulet.com\">awiczek@insulet.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States Netherlands North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Technology Medical Devices Medical Supplies Diabetes Clinical Trials Health Technology Software Health Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250316052311\/en\/1711909\/3\/INSULET_Logo_RGB_No_tag.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes ACTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod\u00ae brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) taking place March 19 \u2013 22, 2025 in Amsterdam, the Netherlands, and online. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826710","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes ACTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod\u00ae brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) taking place March 19 \u2013 22, 2025 in Amsterdam, the Netherlands, and online. &hellip; Continue reading &quot;From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T10:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes\",\"datePublished\":\"2025-03-18T10:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/\"},\"wordCount\":1209,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/\",\"name\":\"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-18T10:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/","og_locale":"en_US","og_type":"article","og_title":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk","og_description":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes ACTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod\u00ae brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) taking place March 19 \u2013 22, 2025 in Amsterdam, the Netherlands, and online. &hellip; Continue reading \"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T10:03:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes","datePublished":"2025-03-18T10:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/"},"wordCount":1209,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/","name":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-18T10:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250316052311r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/from-injections-to-innovation-insulet-to-present-results-from-a-multinational-randomized-trial-of-direct-transition-from-multiple-daily-injections-to-omnipod-5-in-adults-and-children-w\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"From Injections to Innovation \u2013 Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod\u00ae 5 in Adults and Children with Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826710"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826710\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}